Cargando…
Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]
We had conducted phase 1/2 studies of cancer vaccination therapy using neo-tumor antigens in patients with refractory/persistent cervical cancer (CC) and ovarian cancer (OC) to assess the feasibility and efficacy. Enrollees must be refractory/persistent disease for usual treatments with Human Leukoc...
Autores principales: | Takeuchi, Satoshi, Kagabu, Masahiro, Shoji, Tadahiro, Nitta, Yukari, Sugiyama, Toru, Sato, Junya, Nakamura, Yusuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671072/ https://www.ncbi.nlm.nih.gov/pubmed/33235818 http://dx.doi.org/10.1080/2162402X.2020.1838189 |
Ejemplares similares
-
Immunotherapy for Uterine Cervical Cancer
por: Kagabu, Masahiro, et al.
Publicado: (2019) -
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
por: Kagabu, Masahiro, et al.
Publicado: (2020) -
Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012) -
A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023) -
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)